Egypt’s pharmaceutical industry has taken a strategic turn with the appointment of Sharif Ahmed El Akhdar as non-executive Chairman of Rameda Pharmaceutical Industries and Diagnostic Reagents, one of the country’s largest generic drug manufacturers. The move follows LVP Pharma—an investment arm of LimeVest, a healthcare-focused platform with operations in Egypt and Saudi Arabia—finalizing a 23.15% stake in the company, marking a significant consolidation of capital and governance within the sector.
The Board of Directors meeting on June 1, 2026, approved El Akhdar’s appointment alongside two additional non-executive members: Dalia El Shal, Vice Chairman and Group CFO of LimeVest Partners Healthcare, and Ahmed Abou Hendia, Founder and Managing Partner of Abou-Hendia Law Firm. The additions bring LimeVest’s influence to the forefront of Rameda’s leadership, reshaping the company’s 13-member board to reflect a balance between institutional shareholders and independent oversight—a structure the company framed as a commitment to “strong corporate governance.”
El Akhdar’s arrival at Rameda underscores a broader trend of foreign and domestic investment targeting Egypt’s healthcare sector, particularly as the country seeks to diversify its economic dependencies amid regional geopolitical shifts. LimeVest, which El Akhdar founded in 2017, has positioned itself as a key player in Egypt’s pharmaceutical and diagnostics markets, leveraging its Saudi-Egyptian focus to navigate both local and Gulf capital flows. The firm’s previous investments include stakes in companies like Total Egypt and PGESCo, with El Akhdar’s background spanning private equity, management consulting, and board leadership in infrastructure and healthcare.
Rameda’s decision to appoint El Akhdar comes as the company prepares to accelerate its regional expansion, particularly in Saudi Arabia, where demand for affordable generics remains robust. The company’s 2025 annual report highlighted a 12% increase in export revenues, with Saudi Arabia and other Gulf markets accounting for nearly 30% of its international sales. Analysts note that LimeVest’s involvement could amplify Rameda’s access to Saudi distribution channels, where Egyptian generics have gained traction amid cost-sensitive procurement policies.
El Shal and Abou Hendia’s appointments further solidify LimeVest’s operational and legal expertise within Rameda’s governance. El Shal, who oversees financial strategy across LimeVest’s healthcare portfolio, brings experience from companies including Alexandria New Medical Center, while Abou Hendia’s legal background—with prior roles at Elsewedy Electric and Cairo Pharmaceuticals—ensures compliance with Egypt’s evolving corporate regulations, particularly those governing foreign investment in strategic sectors.
The transition also marks the end of an era for outgoing Chairman Ayman Abbas, who will remain on the board as a non-executive member. Abbas’s tenure, which spanned over a decade, saw Rameda navigate Egypt’s economic challenges, including currency devaluations and supply chain disruptions, while maintaining its position as a top-10 generic producer in Africa. His continued presence signals continuity amid the governance overhaul, though industry observers suggest the new leadership will prioritize scaling production capacity and digitalization—a focus El Akhdar emphasized in his first public remarks.
“Rameda is exactly the kind of platform we believe in—resilient, well-run, and with significant growth potential,” El Akhdar stated in a company announcement. “Our priority will be institutionalizing best practices, deepening regional partnerships, and ensuring the company remains a trusted name for patients and investors alike.” The statement aligns with LimeVest’s stated strategy of targeting “high-growth, asset-light” sectors in Egypt, where pharmaceuticals have emerged as a stable outlier amid broader economic volatility.
While the appointments do not immediately alter Rameda’s operational control—El Akhdar’s role is non-executive—they reflect a deliberate shift toward aligning the company’s long-term strategy with LimeVest’s regional healthcare ambitions. The move also comes as Egypt’s pharmaceutical sector faces increasing scrutiny over pricing regulations and intellectual property enforcement, areas where LimeVest’s Gulf connections may offer leverage in policy advocacy.
The next phase for Rameda will be defined by its ability to translate governance changes into tangible growth, particularly as it competes with multinational generics producers expanding into North Africa. The company’s next board meeting, scheduled for September 2026, will likely outline specific initiatives under El Akhdar’s leadership, though details remain subject to internal deliberations.
